AGIOS PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
AGIOS PHARMACEUTICALS, INC. (AGIO) had Contract Liability (Deferred Revenue) of $2.50 million as of 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2022-05-05
- 2022-03-31: Contract with Customer, Liability, Current $2.50M.
- 2021-12-31: Contract with Customer, Liability, Current $0.00.
- 2020-12-31: Contract with Customer, Liability, Current $0.00.
- 2020-09-30: Contract with Customer, Liability, Current $0.00.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2022-03-31 | $2.50M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $0.00 10-Q · filed 2022-05-05 |
| 2020-12-31 | $0.00 10-K · filed 2021-02-25 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-30 |
| 2020-03-31 | $4.75M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $10.93M 10-K · filed 2021-02-25 |
| 2019-09-30 | $16.87M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $18.45M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $22.17M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $32.71M 10-K · filed 2021-02-25 |
| 2018-09-30 | $42.14M 10-Q · filed 2018-11-01 |
| 2017-12-31 | $37.84M 10-K · filed 2019-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |